CN103108641B - Sdf-1结合性核酸及其在癌症治疗中的用途 - Google Patents

Sdf-1结合性核酸及其在癌症治疗中的用途 Download PDF

Info

Publication number
CN103108641B
CN103108641B CN201180043233.4A CN201180043233A CN103108641B CN 103108641 B CN103108641 B CN 103108641B CN 201180043233 A CN201180043233 A CN 201180043233A CN 103108641 B CN103108641 B CN 103108641B
Authority
CN
China
Prior art keywords
sdf
nucleic acid
cancer
binding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180043233.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108641A (zh
Inventor
W·普尔施克
F·雅洛世
D·尤尔伯格
S·克卢斯曼
K·布赫纳
C·马什
N·丁斯
D·茨伯拉尔斯奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma AG filed Critical Noxxon Pharma AG
Publication of CN103108641A publication Critical patent/CN103108641A/zh
Application granted granted Critical
Publication of CN103108641B publication Critical patent/CN103108641B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180043233.4A 2010-09-09 2011-09-09 Sdf-1结合性核酸及其在癌症治疗中的用途 Active CN103108641B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10009397.0 2010-09-09
EP10009397 2010-09-09
PCT/EP2011/004554 WO2012031773A1 (en) 2010-09-09 2011-09-09 Sdf-1 binding nucleic acids and the use thereof in cancer treatment

Publications (2)

Publication Number Publication Date
CN103108641A CN103108641A (zh) 2013-05-15
CN103108641B true CN103108641B (zh) 2016-01-13

Family

ID=44653255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180043233.4A Active CN103108641B (zh) 2010-09-09 2011-09-09 Sdf-1结合性核酸及其在癌症治疗中的用途

Country Status (14)

Country Link
US (3) US20130310442A1 (OSRAM)
EP (1) EP2613789B1 (OSRAM)
JP (1) JP6243736B2 (OSRAM)
KR (1) KR101937939B1 (OSRAM)
CN (1) CN103108641B (OSRAM)
AU (1) AU2011300818B2 (OSRAM)
BR (1) BR112013005664B8 (OSRAM)
CA (1) CA2810950C (OSRAM)
DK (1) DK2613789T3 (OSRAM)
ES (1) ES2678497T3 (OSRAM)
MX (1) MX357770B (OSRAM)
RU (1) RU2679495C2 (OSRAM)
SG (2) SG188220A1 (OSRAM)
WO (1) WO2012031773A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2613789B1 (en) * 2010-09-09 2018-04-18 Noxxon Pharma AG Sdf-1 binding nucleic acids and the use thereof in cancer treatment
EP3443095A1 (en) * 2016-04-15 2019-02-20 Noxxon Pharma AG Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. Method for selecting cancer patient for which combination therapy of retinoid and cancer treatment agent will be effective, and combined drug of retinoid and cancer treatment agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796188A (zh) * 2007-08-06 2010-08-04 诺松制药股份公司 Sdf-1结合核酸及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
ATE333896T1 (de) 1998-03-24 2006-08-15 Chugai Pharmaceutical Co Ltd Vaskularisierungsinhibitoren
JP4786793B2 (ja) * 1998-03-30 2011-10-05 ノースウエスト バイオセラピューティクス，インコーポレイティド 腫瘍形成におけるｃｘｃｒ−４遺伝子の役割に基く治療的および診断的応用
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
EP1297121B1 (en) * 2000-06-26 2005-05-04 Wellstat Biologics Corporation Purging of cells using viruses
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20060019917A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
KR100598309B1 (ko) 2001-06-07 2006-07-10 케모센트릭스, 인크. 세포 이동성 검사
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
DK1438321T5 (da) 2001-10-26 2011-02-21 Noxxon Pharma Ag Modificeret L-nukleinsyre
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
JP2006524242A (ja) * 2003-03-27 2006-10-26 エモリー ユニバーシティー Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
MXPA05011022A (es) 2003-04-13 2006-04-27 Enzon Pharmaceuticals Inc Profarmacos oligonucleotidos polimericos.
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
HUE045882T2 (hu) 2004-03-23 2020-01-28 Ascendis Pharma Gmbh Polimer prodrug önmagát lehasító linkerrel
JP5107716B2 (ja) 2004-11-05 2012-12-26 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 分子治療用生分解性リンカー
EP1883651A1 (en) * 2005-05-26 2008-02-06 Rappaport Family Institute For Research in the Medical Sciences Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions
JP2009504788A (ja) * 2005-08-19 2009-02-05 ジェンザイム・コーポレーション 化学療法の強化方法
MX2009000656A (es) * 2006-07-18 2009-03-25 Noxxon Pharma Ag Acidos nucleicos que se fijan a sdf-i.
US8496931B2 (en) * 2006-08-11 2013-07-30 Medarex, Inc. Monoclonal antibodies against stromal derived factor-1 (SDF-1)
CA2662978A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
CA2672944A1 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
EP2613789B1 (en) * 2010-09-09 2018-04-18 Noxxon Pharma AG Sdf-1 binding nucleic acids and the use thereof in cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796188A (zh) * 2007-08-06 2010-08-04 诺松制药股份公司 Sdf-1结合核酸及其用途

Also Published As

Publication number Publication date
SG10201506725QA (en) 2015-10-29
DK2613789T3 (en) 2018-07-23
AU2011300818A1 (en) 2013-03-07
KR101937939B1 (ko) 2019-01-11
RU2679495C2 (ru) 2019-02-11
ES2678497T3 (es) 2018-08-13
MX2013002722A (es) 2013-06-28
CN103108641A (zh) 2013-05-15
BR112013005664B1 (pt) 2021-11-03
MX357770B (es) 2018-07-24
US20130310442A1 (en) 2013-11-21
WO2012031773A1 (en) 2012-03-15
SG188220A1 (en) 2013-04-30
KR20130114094A (ko) 2013-10-16
JP2013540725A (ja) 2013-11-07
EP2613789B1 (en) 2018-04-18
JP6243736B2 (ja) 2017-12-06
US20160095875A1 (en) 2016-04-07
CA2810950A1 (en) 2012-03-15
RU2013115739A (ru) 2014-10-20
BR112013005664B8 (pt) 2023-04-25
US10093934B2 (en) 2018-10-09
CA2810950C (en) 2023-02-14
EP2613789A1 (en) 2013-07-17
BR112013005664A2 (pt) 2020-08-04
AU2011300818B2 (en) 2015-11-12
HK1184699A1 (zh) 2014-01-30
US20160355821A1 (en) 2016-12-08
US9387221B2 (en) 2016-07-12

Similar Documents

Publication Publication Date Title
CN101796188B (zh) Sdf-1结合核酸及其用途
ES2663404T3 (es) Ácidos nucleicos de unión a SDF-1
US12194056B2 (en) CCR7 aptamers and uses thereof
CN103108641B (zh) Sdf-1结合性核酸及其在癌症治疗中的用途
CN121001748A (zh) 可编程dna蛋白水解靶嵌合体及其使用方法
US11359200B2 (en) Cancer treatment by MALAT1 inhibition
US20230146246A1 (en) Method of Modulating the Number and the Distribution of Tumor-Infiltrating Leukocytes in Tumors
HK1184699B (en) Sdf-1 binding nucleic acids and the use thereof in cancer treatment
HK1144956B (en) Sdf-1 binding nucleic acids and the use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184699

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1184699

Country of ref document: HK

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Berlin, Germany

Patentee after: TME Pharmaceutical Co.,Ltd.

Address before: Berlin, Germany

Patentee before: NOXXON PHARMA AG